{"id":24305,"date":"2022-11-16T02:04:00","date_gmt":"2022-11-15T18:04:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24305"},"modified":"2025-01-31T02:09:39","modified_gmt":"2025-01-30T18:09:39","slug":"gracells-fastcar-platform-wins-fierce-life-sciences-innovation-award","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24305","title":{"rendered":"Gracell&#8217;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award"},"content":{"rendered":"\n<p>China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year\u2019s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm\u2019s Q3 earnings conference call. The FasTCAR platform enables the \u201cnext-day manufacture\u201d of autologous chimeric antigen receptor (CAR) T cell therapies, a significant advancement over the standard CAR-T development process that typically requires 1-2 weeks.<\/p>\n\n\n\n<p><strong>Award Details<\/strong><br>Hosted by the US-based Fierce Pharma industry media platform, the Fierce Innovation Awards are selected annually by a panel of independent judges. The awards aim to highlight organizations that have demonstrated innovative technologies and services with the potential to make a significant impact on healthcare and life sciences companies. Last year\u2019s award in the same category went to US-based Arvinas for its PROTAC targeted protein degradation development platform.<\/p>\n\n\n\n<p><strong>CEO Commentary<\/strong><br>Dr. Cao commented on the award, stating, \u201cFasTCAR was developed with a deep understanding of the challenges faced by conventional CAR T, and we firmly believe this technology, as well as the BCMA\/CD19 dual-targeting CAR T GC012F developed on the FasTCAR platform, represent the innovation that could broaden the use and accessibility of CAR T.\u201d<\/p>\n\n\n\n<p><strong>Future Plans<\/strong><br>According to Gracell\u2019s Q3 report, the company plans to file first INDs to both the US FDA and China\u2019s NMPA for GC012F in relapsed\/refractory multiple myeloma (r\/r MM) during Q4 this year. The BCMA\/CD19 CAR-T has been the focus of investigator-initiated studies in both newly diagnosed and r\/r MM as well as B-cell non-Hodgkin\u2019s lymphoma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[840,644],"class_list":["post-24305","post","type-post","status-publish","format-standard","hentry","category-company","tag-fierce-pharma","tag-gracell-biotechnologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gracell&#039;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year\u2019s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm\u2019s Q3 earnings conference call. The FasTCAR platform enables the \u201cnext-day manufacture\u201d of autologous chimeric antigen receptor (CAR) T cell therapies, a significant advancement over the standard CAR-T development process that typically requires 1-2 weeks.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24305\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gracell&#039;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24305\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T18:04:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T18:09:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gracell&#8217;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award\",\"datePublished\":\"2022-11-15T18:04:00+00:00\",\"dateModified\":\"2025-01-30T18:09:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305\"},\"wordCount\":281,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Fierce Pharma\",\"Gracell Biotechnologies\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24305#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24305\",\"name\":\"Gracell's FasTCAR Platform Wins Fierce Life Sciences Innovation Award - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-15T18:04:00+00:00\",\"dateModified\":\"2025-01-30T18:09:39+00:00\",\"description\":\"China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year\u2019s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm\u2019s Q3 earnings conference call. The FasTCAR platform enables the \u201cnext-day manufacture\u201d of autologous chimeric antigen receptor (CAR) T cell therapies, a significant advancement over the standard CAR-T development process that typically requires 1-2 weeks.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24305\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24305#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gracell&#8217;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gracell's FasTCAR Platform Wins Fierce Life Sciences Innovation Award - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year\u2019s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm\u2019s Q3 earnings conference call. The FasTCAR platform enables the \u201cnext-day manufacture\u201d of autologous chimeric antigen receptor (CAR) T cell therapies, a significant advancement over the standard CAR-T development process that typically requires 1-2 weeks.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24305","og_locale":"en_US","og_type":"article","og_title":"Gracell's FasTCAR Platform Wins Fierce Life Sciences Innovation Award","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24305","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-15T18:04:00+00:00","article_modified_time":"2025-01-30T18:09:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24305#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24305"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gracell&#8217;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award","datePublished":"2022-11-15T18:04:00+00:00","dateModified":"2025-01-30T18:09:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24305"},"wordCount":281,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Fierce Pharma","Gracell Biotechnologies"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24305#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24305","url":"https:\/\/flcube.com\/?p=24305","name":"Gracell's FasTCAR Platform Wins Fierce Life Sciences Innovation Award - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-15T18:04:00+00:00","dateModified":"2025-01-30T18:09:39+00:00","description":"China-based Gracell Biotechnologies Inc\u2019s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year\u2019s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm\u2019s Q3 earnings conference call. The FasTCAR platform enables the \u201cnext-day manufacture\u201d of autologous chimeric antigen receptor (CAR) T cell therapies, a significant advancement over the standard CAR-T development process that typically requires 1-2 weeks.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24305#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24305"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24305#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gracell&#8217;s FasTCAR Platform Wins Fierce Life Sciences Innovation Award"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24305"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24305\/revisions"}],"predecessor-version":[{"id":24307,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24305\/revisions\/24307"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}